Efgartigimod (Argenx), a human immunoglobulin (IgG)1 antibody Fc-fragment, is designed to block the neonatal Fc receptor and reduce IgG autoantibody levels. The treatment was originally approved in an intravenous (IV) formulation in December 2021 for patients with generalized myasthenia gravis (gMG) based on significant findings from the phase 3 ADAPT trial (NCT03669588).
Recently presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting, held November 1-4, in Phoenix, Arizona, new interim data from the open label extension (OLE) of the ADAPT-SC+ trial (NCT04818671) assessing a subcutaneous (SC) version of efgartigimod PH20 demonstrated improvements in daily function in treated patients with gMG. Overall, the findings showed that multiple cycles of the treatment were well tolerated and showed strong efficacy, which were consistent with the results observed in using the IV formulation in the ADAPT/ADAPT+trial.
During the meeting, lead author Yuebing Li, MD, PhD, a neurologist in the neuromuscular center at the Cleveland Clinic, sat down in an interview with NeurologyLive® to discuss how the 2 forms of efgartigimod compared with each other in terms of safety and efficacy. He also shared the implications of the FDA approval for patients with gMG, and how it influences the current treatment landscape. Additionally, Li spoke about the ways in which the continuous treatment cycle of efgartigimod impacts the individualization of treatment plans for patients with gMG, and how does relates to the reduction of other immunotherapies.
(www.neurologyl...)
More AANEM Content:
-www.neurologyl...
Негізгі бет Efficacy and Safety of Weekly Subcutaneous Efgartigimod for Myasthenia Gravis
No video
Пікірлер